L-ergothioneine and its combination with metformin attenuates renal dysfunction in type-2 diabetic rat model by activating Nrf2 antioxidant pathway

被引:25
作者
Dare, Ayobami [1 ]
Channa, Mahendra L. [1 ]
Nadar, Anand [1 ]
机构
[1] Univ KwaZulu Natal, Coll Hlth Sci, Sch Lab Med & Med Sci, Dept Physiol, Westville Campus,X54001, Durban, South Africa
基金
欧洲研究理事会;
关键词
Diabetes; L-ergothioneine; Metformin; Kidney; Antioxidants; Cytoprotection; CHRONIC KIDNEY-DISEASE; FACTOR-KAPPA-B; OXIDATIVE STRESS; TRIGLYCERIDES; NEPHROPATHY; BIOMARKERS; PROTECTION; PRESSURE; MELLITUS; HEALTH;
D O I
10.1016/j.biopha.2021.111921
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
L-ergothioneine (L-egt) is a bioactive compound recently approved by the food and drug administration as a supplement. L-egt exerts potent cyto-protective, antioxidant and anti-inflammatory properties in tissues exposed to injury, while metformin is a first-line prescription in type-2 diabetes. Therefore, the present study investigated the protective effect of L-egt alone, or combined with metformin, on renal damage in a type-2 diabetic (T2D) rat model. T2D was induced in male Sprague-Dawley rats using the fructose-streptozotocin rat model. L-egt administration, alone or combined with metformin, began after confirming diabetes and was administered orally for seven weeks. After the experiment, all animals were euthanized by decapitation, blood samples were collected, and both kidneys were excised. Biochemical analysis, Enzyme-link Immunoassay (ELISA), Reverse transcriptase quantitative polymerase chain reaction (RT-qPCR), western blotting, and histological analyses were done to evaluate various biomarkers and structural changes associated with renal damage. Untreated diabetic rats showed loss of kidney functions characterized by increased serum creatinine, blood urea nitrogen, pro-teinuria, triglycerides, lipid peroxidation, inflammation, and decreased antioxidant enzymes. Histological eval-uation showed evidence of fibrosis, mesangial expansion, and damaged basement membrane in the nephrons. However, L-egt alleviates these functional and structural derangements in the kidney, while co-administration with metformin reduced hyperglycemia and improves therapeutic outcomes. Furthermore, L-egt treatment significantly increased the expression of major antioxidant transcription factors, cytoprotective genes and decreased the expression of inflammatory genes in the kidney. Thus, combining L-egt and metformin may improve therapeutic efficacy and be used as an adjuvant therapy to alleviate renal damage in type-2 diabetes.
引用
收藏
页数:12
相关论文
共 71 条
  • [1] The Metformin Mechanism on Gluconeogenesis and AMPK Activation: The Metabolite Perspective
    Agius, Loranne
    Ford, Brian E.
    Chachra, Shruti S.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (09)
  • [2] Natural antioxidants in the treatment and prevention of diabetic nephropathy; a potential approach that warrants clinical trials
    Al-Waili, Noori
    Al-Waili, Hamza
    Al-Waili, Thia
    Salom, Khelod
    [J]. REDOX REPORT, 2017, 22 (03) : 99 - 118
  • [3] Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through modulation of oxidative stress genes expression
    Alhaider, Abdulqader A.
    Korashy, Hesham M.
    Sayed-Ahmed, Mohamed M.
    Mobark, Mohammed
    Kfoury, Hala
    Mansour, Mahmoud A.
    [J]. CHEMICO-BIOLOGICAL INTERACTIONS, 2011, 192 (03) : 233 - 242
  • [4] Kidney Disease in Diabetes Mellitus: Cross-Linking between Hyperglycemia, Redox Imbalance and Inflammation
    Amorim, Rayne Gomes
    Guedes, Glaucevane da Silva
    de Lima Vasconcelos, Sandra Mary
    de Farias Santos, Juliana Celia
    [J]. ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2019, 112 (05) : 577 - 586
  • [5] Antioxidant agents for delaying diabetic kidney disease progression: A systematic review and meta-analysis
    Bolignano, Davide
    Cernaro, Valeria
    Gembillo, Guido
    Baggetta, Rossella
    Buemi, Michele
    D'Arrigo, Graziella
    [J]. PLOS ONE, 2017, 12 (06):
  • [6] Ureña KGC, 2020, UNDERSEA HYPERBAR M, V47, P415, DOI 10.22462/03.07.2020.2
  • [7] Effects of dexmedetomidine on the RhoA/ROCK/Nox4 signaling pathway in renal fibrosis of diabetic rats
    Chen Jihua
    Chen Cai
    Bao Xubin
    Yu Yue
    [J]. OPEN MEDICINE, 2019, 14 (01): : 890 - 898
  • [8] Risk Factors for Heart Failure in Patients With Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated With Bardoxolone Methyl
    Chin, Melanie P.
    Wrolstad, Danielle
    Bakris, George L.
    Chertow, Glenn M.
    de Zeeuw, Dick
    Goldsberry, Angie
    Linde, Peter G.
    McCullough, Peter A.
    McMurray, John J.
    Wittes, Janet
    Meyer, Colin J.
    [J]. JOURNAL OF CARDIAC FAILURE, 2014, 20 (12) : 953 - 958
  • [9] Urinary Markers of Glomerular Injury in Diabetic Nephropathy
    Cohen-Bucay, Abraham
    Viswanathan, Gautham
    [J]. INTERNATIONAL JOURNAL OF NEPHROLOGY, 2012, 2012
  • [10] United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease
    Collins, Allan J.
    Foley, Robert N.
    Gilbertson, David T.
    Chen, Shu-Cheng
    [J]. KIDNEY INTERNATIONAL SUPPLEMENTS, 2015, 5 (01) : 2 - 7